OxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients

Journal of Nephrology

Volumn 24, Issue 5, 2011, Pages 581-588

  Bossola, Maurizio ^a   Tazza, Luigi ^a   Luciani, Giovanna ^a   Tortorelli, Antonio ^a   Tsimikas, Sotirios ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiovascular disease; Hemodialysis; Lipoprotein(a); Oxidized phospholipids; OxPL apoB

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN B100; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CALCIUM CARBONATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOPROTEIN A; MALONALDEHYDE; NITRATE; OXIDIZED LOW DENSITY LIPOPROTEIN; SEVELAMER;

ADULT; AGE; AGED; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS;

AGED; AGED, 80 AND OVER; ANTIGEN-ANTIBODY COMPLEX; APOLIPOPROTEINS B; AUTOANTIBODIES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; ITALY; KIDNEY FAILURE, CHRONIC; LIPOPROTEIN(A); LIPOPROTEINS, LDL; LOGISTIC MODELS; MALE; MALONDIALDEHYDE; MIDDLE AGED; ODDS RATIO; OXIDATION-REDUCTION; OXIDATIVE STRESS; PHOSPHOLIPIDS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 80052686493     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2011.6442     Document Type: Article

References (38)

1. Rucker D, Tonelli M. Cardiovascular risk and management in chronic kidney disease. Nat Rev Nephrol. 2009;5:287-296.
2. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis. 1998;32:853-906.
3. Brunner FP. Selwood NH; on behalf of the EDTA Registry Committee. Profile of patients on RRT in Europe and death rates due to major causes of death groups. Kidney Int Suppl. 1992;42:S4-S15.
4. US Renal Data System 2010. www.usrds.org.
5. Collins AJ, Li S, Ma JZ, Herzog C. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis. 2001;38(Suppl 1):S26-S29.
6. Herzog CA. Sudden cardiac death and acute myocardial infarction in dialysis patients: perspectives of a cardiologist. Semin Nephrol. 2005;25:363-366.
7. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524-1538.
8. Locatelli F, Canaud B, Eckardt K, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 2003;18:1272-1280.
9. Fraley AE, Tsimikas S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol. 2006;17:502-509.
10. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005;353:46-57.
11. Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of oxidized low density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol. 2003;41:360-370.
12. Tsimikas S, Kiechl S, Willeit J, et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol. 2006;47:2219-2228.
13. Tsimikas S, Lau HK, Han KR, et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation. 2004;109:3164-3170.
14. Mayr M, Kiechl S, Tsimikas S, et al. Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study. J Am Coll Cardiol. 2006;47:2436-2443.
15. Tsimikas S, Brilakis ES, Lennon RJ, et al. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res. 2007;48:425-433.
16. Bossola M, Tazza L, Merki E, et al. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis. Blood Purif. 2007;25:457-465.
17. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356(9237):1213-1218.
18. Danesh J, Collons R, Peto R. Lipoprotein(a) and coronary artery disease: meta-analysis of prospective studies. Circulation. 2000;102:1082-1085.
19. Berglund L, Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol. 2004;24:2219-2226.
20. Anuurad E, Boffa MB, Koschinsky ML, et al. Lipoprotein(a): a unique factor for cardiovascular disease. Clin Lab Med. 2006;26:751-772.
21. Longenecker JC, Klag MJ, Marcovina SM, et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol. 2005;16:1794-1802.
22. Emanuele E, Lusignani S, Peros E, et al. Lipoprotein(a)-associated atherothrombotic risk in hemodialysis patients. Am J Nephrol. 2004;24:221-229.
23. Kronenberg F, Neyer U, Lhotta K, et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol. 1999;10:1027-1036.
24. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA. Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant. 1995;10:354-357.
25. Cressman MD, Abood D, O'Neil J, Hoff HF. Lp(a) and premature mortality during chronic hemodialysis treatment. Chem Phys Lipids. 1994;67-68:419-427.
26. Ohashi H, Oda H, Ohno M, Watanabe S, Sakata S. Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients. Kidney Int Suppl. 1999;71:S242-S244.
27. Koch M, Kutkuhn B, Trenkwalder E, et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol. 1997;8:1889-1898.
28. Takayasu O, Shuzo K, Hidekazu M, et al. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol. 2005;16:1141-1148.
29. Navaneethan SD, Nigwekar SU, Perkovic V, Johnson DW, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev. 2009;8:CD004289.
30. Shoenfeld Y, Wu R, Dearing LD, Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation. 2004;110:2552-2558.
31. Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G. Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int. 1994;46:869-876.
32. Shoji T, Kimoto E, Shinohara K, et al. The association of antibodies against oxidized low-density lipoprotein with atherosclerosis in hemodialysis patients. Kidney Int Suppl. 2003;84:S128-S130.
33. Shoji T, Fukumoto M, Kimoto E, et al. Antibody to oxidized low-density lipoprotein and cardiovascular mortality in endstage renal disease. Kidney Int. 2002;62:2230-2237.
34. Cengiz N, Baskin E, Sezgin N, Agras P, Haberal M. Oxidative stress in children on hemodialysis: value of autoantibodies against oxidized low-density lipoprotein. Pediatr Nephrol. 2009;24:387-393.
35. Lobo J, Santos F, Grosso D, et al. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis. Nephron Clin Pract. 2008;108:c298-c304.
36. Mustafa A, Nityanand S, Berglund L, Lithell H, Lefvert AK. Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction. Circulation. 2000;102:2576-2581.
37. Orchard TJ, Virella G, Forrest KY, Evans RW, Becker DJ, Lopes-Virella MF. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1999;48:1454-1458.
38. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German diabetes and dialysis study investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 2005;353(3):238-248.